Fractyl is focused on addressing insulin resistance to improve the health of people with some of the most common metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). Fractyl has developed the REVITA™ duodenal mucosal resurfacing (DMR) system that involves a trans-oral, incision-free procedure to safely alter the mucosa of the small intestine and help improve how the body absorbs and processes nutrients from the diet.